{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470610310
| IUPAC_name = 2-Ethylamino-2-(2-thienyl) cyclohexanone
| image = Tiletamine.svg
| image2 = Tiletamine-ball-and-stick-model.png
| alt2   = (S)-tiletamine

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|tiletamine}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = S4
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Schedule III
| legal_status =  
| routes_of_administration = [[Intravenous therapy|IV]], [[Intramuscular injection|IM]], [[Subcutaneous injection|SC]], Other

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism = Liver
| elimination_half-life =  
| excretion = Kidneys

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 14176-50-2
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 26533
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24714
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2YFC543249
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08596

<!--Chemical data-->
| C=12 | H=17 | N=1 | O=1 | S=1 
| smiles = O=C2C(c1sccc1)(NCC)CCCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = QAXBVGVYDCAVLV-UHFFFAOYSA-N
}}

'''Tiletamine''' is a [[dissociative anesthetic]] and [[pharmacology|pharmacologically]] classified as an [[NMDA receptor antagonist]].<ref>{{cite journal|last1=Klockgether|first1=Thomas|last2=Turski |first2=Lechoslaw |last3=Schwarz |first3=Michael |last4=Sontag |first4=Karl-Heinz |last5=Lehmann |first5=John|title=Paradoxical convulsant action of a novel non-competitiveN-methyl-d-aspartate (NMDA) antagonist, tiletamine|journal=Brain Research |date=1 October 1988 |volume=461 |issue=2 |pages=343–348 |doi=10.1016/0006-8993(88)90265-X|pmid=2846121}}</ref> It is related chemically to [[ketamine]].<ref>{{PubChem|26533}}</ref>  Tiletamine hydrochloride exists as odorless white crystals. 

It is used in [[veterinary medicine]] in the [[combination drug|combination]] product '''Telazol''' (tiletamine/[[zolazepam]], 50&nbsp;mg/ml of each in 5 ml vial) as an injectable anesthetic for use in [[cat]]s and [[dog]]s.<ref name=Tiletamine>{{cite web|title=Tiletamine entry at Drugs.com|url=http://www.drugs.com/international/tiletamine.html|accessdate=5 January 2012}}</ref><ref>{{cite journal | pmid = 8126757| year = 1993| author1 = Lin| first1 = H. C| title = Telazol--a review of its pharmacology and use in veterinary medicine| journal = Journal of veterinary pharmacology and therapeutics| volume = 16| issue = 4| pages = 383–418| last2 = Thurmon| first2 = J. C| last3 = Benson| first3 = G. J| last4 = Tranquilli| first4 = W. J}}</ref><ref>NIH [http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+14176-49-9 Tiletamine entry in Toxnet] Page last reviewed 1/21/2009</ref>  It is sometimes used in combination with [[xylazine]] (Rompun) to tranquilize large [[mammal]]s such as [[polar bear]]s<ref>{{cite journal|last1=Cattet|first1=M.R.|last2=Caulkett |first2=N.A. |last3=Lunn |first3=N.J.|title=Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine |journal=Journal of wildlife diseases|date=July 2003 |volume=39 |issue=3 |pages=655–64 |pmid=14567228 |doi=10.7589/0090-3558-39.3.655}}</ref> and [[wood bison]].<ref>{{cite journal|last1=Caulkett|first1=N.A.|last2=Cattet |first2=M.R. |last3=Cantwell |first3=S. |last4=Cool |first4=N. |last5=Olsen |first5=W.|title=Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations.|journal=The Canadian Veterinary Journal/La revue veterinaire canadienne|date=January 2000|volume=41|issue=1|pages=49–53|pmid=10642872|pmc=1476335}}</ref> Telazol is the only commercially available tiletamine product in the [[United States]]. It is contraindicated in patients of an [[ASA score]] of III or greater and in animals with CNS signs, hyperthyroidism, cardiac disease, pancreatic or renal disease, pregnancy, [[glaucoma]], or penetrating eye injuries.<ref name=Tiletamine/>

Abuse of Telazol has been documented.<ref>{{cite journal|last=Quail|first=MT|author2=Weimersheimer, P |author3=Woolf, AD |author4=Magnani, B |title=Abuse of telazol: an animal tranquilizer.|journal=Journal of Toxicology: Clinical Toxicology|year=2001|volume=39|issue=4|pages=399–402|pmid=11527235|doi=10.1081/clt-100105161}}</ref> Animal studies have also shown that tiletamine produces rewarding and reinforcing effects.<ref>{{cite journal |vauthors=de la Peña JB, Lee HC, de la Peña IC, Woo TS, Yoon SY, Lee HL, Han JS, Lee JI, Cho YJ, Shin CY, Cheong JH |title=Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, Zoletil®: difference between acute and repeated exposure |journal=Behavioural Brain Research |volume=233 |issue=2 |pages=434–42 |year=2012 |pmid=22659394 |doi=10.1016/j.bbr.2012.05.038 }}</ref> Tiletamine products are classified as [[Controlled Substances Act#Schedule III controlled substances|Schedule III]] [[controlled substance]]s in the United States.<ref>{{cite web|title=Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals|url=http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|publisher=Drug Enforcement Administration|accessdate=5 January 2012}}</ref>

==References==
{{Reflist|2}}

==External links==
* [http://www.erowid.org/pharms/tiletamine/tiletamine.shtml Erowid: Telazol]


{{General anesthetics}}
{{Hallucinogens}}
{{Ionotropic glutamate receptor modulators}}

[[Category:Dissociative drugs]]
[[Category:General anesthetics]]
[[Category:Ketones]]
[[Category:NMDA receptor antagonists]]
[[Category:Thiophenes]]